Compare AU
Compare CURE vs. STW
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the SPDR S&P/ASX 200 Fund (STW). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | STW | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 359 |
Median incremental investment | $624.65 | $1,007.09 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,353.14 | $4,503.04 |
Average age group | > 35 | > 35 |
Key Summary
CURE | STW | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | STW.AX was created on 2001-08-24 by SPDR. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 5544.33m in AUM and 204 holdings. The SPDR S&P/ASX 200 Fund, seeks to closely match, before fees and expenses, the returns of the S&P/ASX 200 Index. |
Top 3 holdings | AbbVie Inc (2.62 %) Alnylam Pharmaceuticals Inc (2.59 %) Amgen Inc (2.59 %) | Commonwealth Bank of Australia (10.53 %) BHP Group Ltd (8.15 %) CSL Ltd (5.18 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Financials (55.31 %) Materials (17.25 %) Health Care (10.69 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | Australia (94.83 %) United States (3.10 %) New Zealand (1.58 %) |
Management fee | 0.45 % | 0.05 % |
Key Summary
CURE | STW | |
|---|---|---|
Issuer | Global X | SPDR |
Tracking index | S&P Biotechnology Select Industry | S&P ASX 200 |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.05 % |
Price | $46.66 | $70.36 |
Size | $33.491 million | $5.562 billion |
10Y return | N/A | 29.27 % |
Annual distribution yield (5Y) | 4.24 % | 5.67 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 27/08/2001 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | STW | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 359 |
Median incremental investment | $624.65 | $1,007.09 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,353.14 | $4,503.04 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | STW | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | STW |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |